DECOY THERAPEUTICS INC
DCOYNASDAQπ #5325 by market capUS Equity
$0.87β
Last available close Β· quote unavailableTrack DCOY
Get earnings, price moves & breaking news on Telegram
24hβ
7dβΌ 9.4%
14dβΌ 22.7%
30dβΌ 12.1%
ytdβΌ 88.7%
1yβΌ 91.7%
π¦Market Cap
$441,214
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
-2678.4%
Thin
π΅FCF Margin
-3053.6%
Thin
βοΈP/S Ratio
1.4x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $0.80 β $16.92
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 531,967
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $307,430
- P/E Ratio
- -0.0
- P/S Ratio
- 1.4x
- EPS (TTM)
- $-19.59
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +6544.6%
DECOY THERAPEUTICS INC
DCOYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$13Mβ² +120.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$5Mβ² +6.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
532Kβ² +6544.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11Mβ² +$8M YoY
About DECOY THERAPEUTICS INC
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.